Table 3.

YMRS Scores at Baseline and Change from Baseline

	RCT		OLE
n	Ziprasidone 149	Placebo 88	Ziprasidone 162
Baseline
n	143	86	162
Mean (SD)	26.2 (6.6)	27.0 (6.6)	16.5 (10.2)
Change from baseline at end of study–LOCF
n	133	85	153
Mean (SD)	−12.8 (8.4)	−7.1 (7.8)	−3.3 (10.7)

For RCT, baseline is day 1 of study and end of study is week 4. For OLE, baseline is last available observation from the double-blind study and end of study is week 26.

OLE, open-label extension; RCT, randomized controlled trial; LOCF, last observation carried forward.